Search

Your search keyword '"Tan, A.C.I.T.L."' showing total 28 results
Start Over Author "Tan, A.C.I.T.L."
28 results on '"Tan, A.C.I.T.L."'

1. Development of pancreatic diseases during long-term follow-up of patients with acute pancreatitis in a prospective nationwide cohort

Author

de Rijk, F.E.M., primary, Sissingh, N.J., additional, Boel, T.T., additional, Timmerhuis, H.C., additional, de Jong, M.J.P., additional, Pauw, H.A., additional, van Veldhuisen, C.L., additional, Hallensleben, N.D., additional, Anten, M.P., additional, Brink, M.A., additional, Curvers, W.L., additional, van Duijvendijk, P., additional, Hazen, W.L., additional, Kuiken, S.D., additional, Poen, A.C., additional, Quispel, R., additional, Romkens, T.E.H., additional, Spanier, B.W.M., additional, Tan, A.C.I.T.L., additional, Vleggaar, F.P., additional, Voorburg, A.M.C.J., additional, Witteman, B.J.M., additional, Ali, U Ahmed, additional, Issa, Y., additional, Bouwense, S.A.W., additional, Voermans, R.P., additional, van Geenen, E.J.M., additional, van Hooft, J.E., additional, de Jonge, P.J., additional, van Goor, H., additional, Boermeester, M.A., additional, Besselink, M.G., additional, Bruno, M.J., additional, Verdonk, R.C., additional, and van Santvoort, H.C., additional

Published
2023
Full Text
View/download PDF

2. Patient selection for urgent endoscopic retrograde cholangio-pancreatography by endoscopic ultrasound in predicted severe acute biliary pancreatitis (APEC-2): a multicentre prospective study.

Author

Hallensleben, N.D., Stassen, P.M.C., Schepers, N.J., Besselink, M.G., Anten, M.G.F., Bakker, O.J., Bollen, T.L., Costa, D.W. da, Dijk, S.M. van, Dullemen, H.M. van, Dijkgraaf, M.G.W., Eijck, B. van, Eijck, C.H.J. van, Erkelens, W., Erler, N.S., Fockens, P., Geenen, E.J.M. van, Grinsven, J. van, Hazen, W.L., Hollemans, R.A., Hooft, J.E. van, Jansen, Jeroen M., Kubben, F.J.G.M., Kuiken, S.D., Poen, A.C., Quispel, R., Ridder, R.J. de, Römkens, T.E.H., Schoon, E.J., Schwartz, M.P., Seerden, T.C.J., Smeets, X.J.N.M., Spanier, B.W.M., Tan, A.C.I.T.L., Thijs, W.J., Timmer, R., Umans, D.S., Venneman, N.G., Verdonk, R.C., Vleggaar, F.P., Vrie, W. van de, Wanrooij, R.L.J. van, Witteman, B.J., Santvoort, H.C. van, Bouwense, S.A.W., Bruno, M.J., Hallensleben, N.D., Stassen, P.M.C., Schepers, N.J., Besselink, M.G., Anten, M.G.F., Bakker, O.J., Bollen, T.L., Costa, D.W. da, Dijk, S.M. van, Dullemen, H.M. van, Dijkgraaf, M.G.W., Eijck, B. van, Eijck, C.H.J. van, Erkelens, W., Erler, N.S., Fockens, P., Geenen, E.J.M. van, Grinsven, J. van, Hazen, W.L., Hollemans, R.A., Hooft, J.E. van, Jansen, Jeroen M., Kubben, F.J.G.M., Kuiken, S.D., Poen, A.C., Quispel, R., Ridder, R.J. de, Römkens, T.E.H., Schoon, E.J., Schwartz, M.P., Seerden, T.C.J., Smeets, X.J.N.M., Spanier, B.W.M., Tan, A.C.I.T.L., Thijs, W.J., Timmer, R., Umans, D.S., Venneman, N.G., Verdonk, R.C., Vleggaar, F.P., Vrie, W. van de, Wanrooij, R.L.J. van, Witteman, B.J., Santvoort, H.C. van, Bouwense, S.A.W., and Bruno, M.J.

Abstract

01 augustus 2023, Contains fulltext : 294877.pdf (Publisher’s version ) (Closed access), OBJECTIVE: Routine urgent endoscopic retrograde cholangiopancreatography (ERCP) with endoscopic biliary sphincterotomy (ES) does not improve outcome in patients with predicted severe acute biliary pancreatitis. Improved patient selection for ERCP by means of endoscopic ultrasonography (EUS) for stone/sludge detection may challenge these findings. DESIGN: A multicentre, prospective cohort study included patients with predicted severe acute biliary pancreatitis without cholangitis. Patients underwent urgent EUS, followed by ERCP with ES in case of common bile duct stones/sludge, within 24 hours after hospital presentation and within 72 hours after symptom onset. The primary endpoint was a composite of major complications or mortality within 6 months after inclusion. The historical control group was the conservative treatment arm (n=113) of the randomised APEC trial (Acute biliary Pancreatitis: urgent ERCP with sphincterotomy versus conservative treatment, patient inclusion 2013-2017) applying the same study design. RESULTS: Overall, 83 patients underwent urgent EUS at a median of 21 hours (IQR 17-23) after hospital presentation and at a median of 29 hours (IQR 23-41) after start of symptoms. Gallstones/sludge in the bile ducts were detected by EUS in 48/83 patients (58%), all of whom underwent immediate ERCP with ES. The primary endpoint occurred in 34/83 patients (41%) in the urgent EUS-guided ERCP group. This was not different from the 44% rate (50/113 patients) in the historical conservative treatment group (risk ratio (RR) 0.93, 95% CI 0.67 to 1.29; p=0.65). Sensitivity analysis to correct for baseline differences using a logistic regression model also showed no significant beneficial effect of the intervention on the primary outcome (adjusted OR 1.03, 95% CI 0.56 to 1.90, p=0.92). CONCLUSION: In patients with predicted severe acute biliary pancreatitis without cholangitis, urgent EUS-guided ERCP with ES did not reduce the composite endpoint of major complications

Published
2023

3. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease

Author

Masclee, A.A.M., Pierik, M., Mares, W., Hameeteman, W., Wahab, P.J., Seinen, H., Rijk, M.C.M., Harkema, I.M., de Bièvre, M., Oostenbrug, L., Bakker, C.M., Aquarius, M., van Deursen, C., van Nunen, A.B., Goedhard, J.G., Hamacher, M., Gisbertz, I.A.M., Brenninkmeijer, B.J., Tan, A.C.I.T.L., Aparicio-Pagés, M.N., Witteman, E.M., van Tuyl, S.A.C., Breumelhof, R., Stronkhorst, A., Gilissen, L.P.L., Schoon, E.J., Tjhie-Wensing, J.W.M., Temmerman, A., Nicolaï, J.J., van Bergeijk, J.D., Bac, D.J., Witteman, B.J.M., Mahmmod, N., Uil, J.J., Akol, H., Ouwendijk, R.J.T., van Munster, I.P., Pennings, M., De Schryver, A.M.P., van Ditzhuijsen, T.J.M., Scheffer, R.C.H., Römkens, T.E.H., Schipper, D.L., Bus, P.J., Straathof, J.W.A., Verhulst, M.L., Boekema, P.J., Kamphuis, J.T., van Wijk, H.J., Salemans, J.M.J.L., Vermeijden, J.R., van der Werf, S.D.J., Verburg, R.J., Spoelstra, P., de Vree, J.M.L., van der Linde, K., Jebbink, H.J.A., Jansen, M., Holwerda, H., van Bentem, N., Kolkman, J.J., Russel, M.G.V.M., van Olffen, G.H., Kerbert-Dreteler, M.J., Bargeman, M., Götz, J.M., Schröder, R., Jansen, J.M., Bos, L.P., Engels, L.G.J.B., Romberg-Camps, M.J.L., Keulen, E.T.P., van Esch, A.A.J., Drenth, J.P.H., van Kouwen, M.C.A., Wanten, G.J.A., Bisseling, T.J., van Vugt, M.W.J., van de Meeberg, P.C., van den Hazel, S.J., Stuifbergen, W.N.H.M., Grubben, M.J.A.L., de Wit, U., Dodemont, G.A.H., Eichhorn, R.F., van den Brande, J.M.H., Naber, A. H.J., van Soest, E.J., Kingma, P.J., Talstra, N.C., Bruin, K.F., Wolfhagen, F.H.J., Hommes, D.W., van der Veek, P.P.J., Hardwick, J.C.A., Stuyt, R.J., Fidder, H.H., Oldenburg, B., Tan, T.G., Coenen, Marieke J.H., de Jong, Dirk J., van Marrewijk, Corine J., Derijks, Luc J.J., Vermeulen, Sita H., Wong, Dennis R., Klungel, Olaf H., Verbeek, Andre L.M., Hooymans, Piet M., Peters, Wilbert H.M., te Morsche, Rene H.M., Newman, William G., Scheffer, Hans, Guchelaar, Henk-Jan, and Franke, Barbara

Published
2015
Full Text
View/download PDF

4. Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease

Author

Huinink, S.T., Jong, D.C. de, Nieboer, D., Thomassen, D., Steyerberg, E.W., Dijkgraaf, M.G.W., Bodelier, A.G.L., West, R.L., Romkens, T.E.H., Hoentjen, F., Mallant, R.C., Tuyl, B.A.C. van, Mares, W.G.N., Wolfhagen, F.H.J., Dijkstra, G., Reijnders, J.G.P., Boer, N.K. de, Tan, A.C.I.T.L., Boeckel, P.G.A. van, Tack, G.J., Asseldonk, D.P. van, D'Haens, G.R.A.M., Woude, C.J. van der, Duijvestein, M., Vries, A.C. de, Groningen Institute for Organ Transplantation (GIOT), Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Translational Immunology Groningen (TRIGR), Gastroenterology and Hepatology, Graduate School, Epidemiology and Data Science, APH - Methodology, Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and hepatology, Gastroenterology & Hepatology, Public Health, and Surgery

Subjects
anti-TNF therapy, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], Risk Assessment, All institutes and research themes of the Radboud University Medical Center, Crohn Disease, Recurrence, Humans, METAANALYSIS, Retrospective Studies, Models, Statistical, Hepatology, FACTOR-ALPHA THERAPY, Gastroenterology, Reproducibility of Results, REMISSION, prediction, EFFICACY, BREAST-CANCER RISK, Crohn's disease, MAINTENANCE, cessation, Withholding Treatment, SAFETY, ANTITUMOR NECROSIS FACTOR, Tumor Necrosis Factor Inhibitors, WITHDRAWAL, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], INFLAMMATORY-BOWEL-DISEASE
Abstract

BACKGROUND: Anti-tumor necrosis factor (TNF) therapy is effective for the treatment of Crohn's disease. Cessation may be considered in patients with a low risk of relapse. We aimed to externally validate and update our previously developed prediction model to estimate the risk of relapse after cessation of anti-TNF therapy. METHODS: We performed a retrospective cohort study in 17 Dutch hospitals. Crohn's disease patients in clinical, biochemical or endoscopic remission were included after anti-TNF cessation. Primary outcome was a relapse necessitating treatment. Discrimination and calibration of the previously developed model were assessed. After external validation, the model was updated. The performance of the updated prediction model was assessed in internal-external validation and by using decision curve analysis. RESULTS: 486 patients were included with a median follow-up of 1.7 years. Relapse rates were 35 and 54% after 1 and 2 years. At external validation, the discriminative ability of the prediction model was equal to that found at the development of the model [c-statistic 0.58 (95% confidence interval (CI) 0.54-0.62)], though the model was not well-calibrated on our cohort [calibration slope: 0.52 (0.28-0.76)]. After an update, a c-statistic of 0.60 (0.58-0.63) and calibration slope of 0.89 (0.69-1.09) were reported in internal-external validation. CONCLUSION: Our previously developed and updated prediction model for the risk of relapse after cessation of anti-TNF in Crohn's disease shows reasonable performance. The use of the model may support clinical decision-making to optimize patient selection in whom anti-TNF can be withdrawn. Clinical validation is ongoing in a prospective randomized trial.

Published
2022
Full Text
View/download PDF

5. Clip placement to prevent delayed bleeding after colonic endoscopic mucosal resection (CLIPPER): study protocol for a randomized controlled trial

Author

Turan, A.S., Moons, L.M.G., Schreuder, R.M., Schoon, E.J., Droste, J.S.T.S., Schrauwen, R.W.M., Straathof, J.W., Bastiaansen, B.A.J., Schwartz, M.P., Hazen, W.L., Alkhalaf, A., Allajar, D., Hadithi, M., Spek, B.W. van der, Heine, D.G.D.N., Tan, A.C.I.T.L., Graaf, W. de, Boonstra, J.J., Voogd, F.J., Roomer, R., Ridder, R.J.J. de, Kievit, W., Siersema, P.D., Didden, P., Geenen, E.J.M. van, Dutch EMR Study Grp, RS: FHML non-thematic output, MUMC+: MA Maag Darm Lever (9), Interne Geneeskunde, Gastroenterology & Hepatology, Gastroenterology and Hepatology, CCA - Cancer Treatment and Quality of Life, and Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
Colorectal cancer, medicine.medical_treatment, Medicine (miscellaneous), Endoscopic mucosal resection, law.invention, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Study Protocol, HEMORRHAGE, 0302 clinical medicine, Randomized controlled trial, law, Multicenter Studies as Topic, Medicine, Pharmacology (medical), POLYPECTOMY, CLIPS, Clipper (electronics), Netherlands, Randomized Controlled Trials as Topic, computer.programming_language, lcsh:R5-920, Incidence (epidemiology), Colonoscopy, Surgical Instruments, surgical procedures, operative, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, POSTPOLYPECTOMY, lcsh:Medicine (General), medicine.medical_specialty, Endoscopic Mucosal Resection, Colon, emr, Colonic Polyps, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], Postoperative Hemorrhage, digestive system, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, prophylactic clipping, Humans, Colonic polyp, Clip artifact, business.industry, COLORECTAL LESIONS, Clipping (medicine), medicine.disease, Surgery, LARGE SESSILE, CLOSURE, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], RISK-FACTORS, Delayed bleeding, business, Complication, computer, COSTS
Abstract

Background Endoscopic mucosal resection (EMR) for large colorectal polyps is in most cases the preferred treatment to prevent progression to colorectal carcinoma. The most common complication after EMR is delayed bleeding, occurring in 7% overall and in approximately 10% of polyps ≥ 2 cm in the proximal colon. Previous research has suggested that prophylactic clipping of the mucosal defect after EMR may reduce the incidence of delayed bleeding in polyps with a high bleeding risk. Methods The CLIPPER trial is a multicenter, parallel-group, single blinded, randomized controlled superiority study. A total of 356 patients undergoing EMR for large (≥ 2 cm) non-pedunculated polyps in the proximal colon will be included and randomized to the clip group or the control group. Prophylactic clipping will be performed in the intervention group to close the resection defect after the EMR with a distance of Discussion The CLIPPER trial is a pragmatic study performed in the Netherlands and is powered to determine the real-time efficacy and cost-effectiveness of prophylactic clipping after EMR of proximal colon polyps ≥ 2 cm in the Netherlands. This study will also generate new data on the achievability of complete closure and the effects of clip placement on scar surveillance after EMR, in order to further promote the debate on the role of prophylactic clipping in everyday clinical practice. Trial registration ClinicalTrials.gov NCT03309683. Registered on 13 October 2017. Start recruitment: 05 March 2018. Planned completion of recruitment: 31 August 2021.

Published
2021

6. Clip placement to prevent delayed bleeding after colonic endoscopic mucosal resection (CLIPPER): study protocol for a randomized controlled trial

Author

Turan, A.S. (Ayla S.), Moons, L.M.G. (Leon), Schreuder, R.-M. (Ramon-Michel), Schoon, E.J. (Erik), Terhaar sive Droste, J.S. (Jochim), Schrauwen, R.W.M. (Ruud W. M.), Straathof, J.W.A., Bastiaansen, D. (Dennis), Schwartz, M.P. (Matthijs), Hazen, W.L. (Wouter L.), Alkhalaf, A. (Alaa), Allajar, D. (Daud), Hadithi, M. (Muhammed), van der Spek, B.W., Heine, D.G.D.N. (Dimitri G. D. N.), Tan, A.C.I.T.L. (Adriaan C. I. T. L.), de Graaf, W. (Wilmar), Boonstra, J.J. (Jurjen), Voogd, F.J. (Fia J.), Roomer, R. (Robert), Ridder, R. (Rogier) de, Kievit, W. (Wietske), Siersema, P.D. (Peter), Didden, P. (Paul), Geenen, E-J.M. (Erwin-Jan), Turan, A.S. (Ayla S.), Moons, L.M.G. (Leon), Schreuder, R.-M. (Ramon-Michel), Schoon, E.J. (Erik), Terhaar sive Droste, J.S. (Jochim), Schrauwen, R.W.M. (Ruud W. M.), Straathof, J.W.A., Bastiaansen, D. (Dennis), Schwartz, M.P. (Matthijs), Hazen, W.L. (Wouter L.), Alkhalaf, A. (Alaa), Allajar, D. (Daud), Hadithi, M. (Muhammed), van der Spek, B.W., Heine, D.G.D.N. (Dimitri G. D. N.), Tan, A.C.I.T.L. (Adriaan C. I. T. L.), de Graaf, W. (Wilmar), Boonstra, J.J. (Jurjen), Voogd, F.J. (Fia J.), Roomer, R. (Robert), Ridder, R. (Rogier) de, Kievit, W. (Wietske), Siersema, P.D. (Peter), Didden, P. (Paul), and Geenen, E-J.M. (Erwin-Jan)

Abstract

Background: Endoscopic mucosal resection (EMR) for large colorectal polyps is in most cases the preferred treatment to prevent progression to colorectal carcinoma. The most common complication after EMR is delayed bleeding, occurring in 7% overall and in approximately 10% of polyps ≥ 2 cm in the proximal colon. Previous research has suggested that prophylactic clipping of the mucosal defect after EMR may reduce the incidence of delayed bleeding in polyps with a high bleeding risk. Methods: The CLIPPER trial is a multicenter, parallel-group, single blinded, randomized controlled superiority study. A total of 356 patients undergoing EMR for large (≥ 2 cm) non-pedunculated polyps in the proximal colon will be included and randomized to the clip group or the control group. Prophylactic clipping will be performed in the intervention group to close the resection defect after the EMR with a distance of < 1 cm between the clips. Primary outcome is delayed bleeding within 30 days after EMR. Secondary outcomes are recurrent or residual polyps and clip artifacts during surveillance colonoscopy after 6 months, as well as cost-effectiveness of prophylactic clipping and severity of delayed bleeding. Discussion: The CLIPPER trial is a pragmatic study performed in the Netherlands and is powered to determine the real-time efficacy and cost-effectiveness of prophylactic clipping after EMR of proximal colon polyps ≥ 2 cm in the Netherlands. This study will also generate new data on the achievability of complete closure and the effects of clip placement on scar surveillance after EMR, in order to further promote the debate on the role of prophylactic clipping in everyday clinical practice. Trial registration: ClinicalTrials.gov NCT03309683. Registered on 13 October 2017. Start recruitment: 05 March 2018. Planned completion of recruitment: 31 August 2021.

Published
2021
Full Text
View/download PDF

7. Web-Based Educational Intervention for Patients With Uninvestigated Dyspepsia Referred for Upper Gastrointestinal Tract Endoscopy: A Randomized Clinical Trial

Author

de Jong, J.J., de Jong, J.J., Lantinga, M.A., Tan, A.C.I.T.L., Aquarius, M., Scheffer, R.C.H., Uil, J.J., de Reuver, P.R., Keszthelyi, D., Westert, G.P., Masclee, A.A.M., Drenth, J.P.H., de Jong, J.J., de Jong, J.J., Lantinga, M.A., Tan, A.C.I.T.L., Aquarius, M., Scheffer, R.C.H., Uil, J.J., de Reuver, P.R., Keszthelyi, D., Westert, G.P., Masclee, A.A.M., and Drenth, J.P.H.

Abstract

IMPORTANCE Diagnostic yield of upper gastrointestinal (GI) tract endoscopy for uninvestigated dyspepsia is low, and its clinical implications are limited. There is an unmet need for better strategies to reduce the volume of upper GI tract endoscopic procedures for dyspepsia.OBJECTIVE To study the effectiveness of a web-based educational intervention as a tool to reduce upper GI tract endoscopy in uninvestigated dyspepsia.DESIGN, SETTING, AND PARTICIPANTS This open-label, multicenter, randomized clinical trial enrolled participants between November 1, 2017, and March 31, 2019, with follow-up 52 weeks after randomization, at 4 teaching hospitals in the Netherlands. Participants included patients with uninvestigated dyspeptic symptoms who were referred for upper GI tract endoscopy by their general health care clinician without prior consultation of a gastroenterologist. A total of 119 patients, aged 18 to 69 years, were included. Patients were excluded if any of the following red flag symptoms were present: (indirect) signs of upper GI tract hemorrhage (hematemesis, melena, hematochezia, or anemia), unintentional weight loss of 5% or higher of normal body weight during a period of 6 to 12 months, persistent vomiting, dysphagia, or jaundice.INTERVENTIONS Patients were randomly assigned (1:1) to education (intervention) or upper GI tract endoscopy (control). Education consisted of a self-managed web-based educational intervention, containing information on gastric function, dyspepsia, and upper GI tract endoscopy.MAIN OUTCOMES AND MEASURES Difference in the proportion of upper GI tract endoscopy procedures between those who received access to the web-based educational intervention and those who did not at 12 weeks and 52 weeks after randomization, analyzed in the intention-to-treat population. Secondary outcomes included quality of life (Nepean Dyspepsia Index) and symptom severity (Patient Assessment of Gastrointestinal Disorders Symptom S

Published
2021

8. Urgent endoscopic retrograde cholangiopancreatography with sphincterotomy versus conservative treatment in predicted severe acute gallstone pancreatitis (APEC): a multicentre randomised controlled trial

Author

Schepers, N.J., Schepers, N.J., Hallensleben, N.D.L., Besselink, M.G., Anten, M.P.G.F., Bollen, T.L., da Costa, D.W., van Delft, F., van Dijk, S.M., van Dullemen, H.M., Dijkgraaf, M.G.W., van Eijck, C.H.J., Erkelens, G.W., Erler, N.S., Fockens, P., van Geenen, E.J.M., van Grinsven, J., Hollemans, R.A., van Hooft, J.E., van der Hulst, R.W.M., Jansen, J.M., Kubben, F.J.G.M., Kuiken, S.D., Laheij, R.J.F., Quispel, R., de Ridder, R.J.J., Rijk, M.C.M., Romkens, T.E.H., Ruigrok, C.H.M., Schoon, E.J., Schwartz, M.P., Smeets, X.J.N.M., Spanier, B.W.M., Tan, A.C.I.T.L., Thijs, W.J., Timmer, R., Venneman, N.G., Verdonk, R.C., Vleggaar, F.P., van de Vrie, W., Witteman, B., van Santvoort, H.C., Bakker, O.J., Bruno, M.J., Dutch Pancreatitis Study Grp, Schepers, N.J., Schepers, N.J., Hallensleben, N.D.L., Besselink, M.G., Anten, M.P.G.F., Bollen, T.L., da Costa, D.W., van Delft, F., van Dijk, S.M., van Dullemen, H.M., Dijkgraaf, M.G.W., van Eijck, C.H.J., Erkelens, G.W., Erler, N.S., Fockens, P., van Geenen, E.J.M., van Grinsven, J., Hollemans, R.A., van Hooft, J.E., van der Hulst, R.W.M., Jansen, J.M., Kubben, F.J.G.M., Kuiken, S.D., Laheij, R.J.F., Quispel, R., de Ridder, R.J.J., Rijk, M.C.M., Romkens, T.E.H., Ruigrok, C.H.M., Schoon, E.J., Schwartz, M.P., Smeets, X.J.N.M., Spanier, B.W.M., Tan, A.C.I.T.L., Thijs, W.J., Timmer, R., Venneman, N.G., Verdonk, R.C., Vleggaar, F.P., van de Vrie, W., Witteman, B., van Santvoort, H.C., Bakker, O.J., Bruno, M.J., and Dutch Pancreatitis Study Grp

Abstract

Background It remains unclear whether urgent endoscopic retrograde cholangiopancreatography (ERCP) with biliary sphincterotomy improves the outcome of patients with gallstone pancreatitis without concomitant cholangitis. We did a randomised trial to compare urgent ERCP with sphincterotomy versus conservative treatment in patients with predicted severe acute gallstone pancreatitis.Methods In this multicentre, parallel-group, assessor-masked, randomised controlled superiority trial, patients with predicted severe (Acute Physiology and Chronic Health Evaluation II score >= 8, Imrie score >= 3, or C-reactive protein concentration >150 mg/L) gallstone pancreatitis without cholangitis were assessed for eligibility in 26 hospitals in the Netherlands. Patients were randomly assigned (1:1) by a web-based randomisation module with randomly varying block sizes to urgent ERCP with sphincterotomy (within 24 h after hospital presentation) or conservative treatment. The primary endpoint was a composite of mortality or major complications (new-onset persistent organ failure, cholangitis, bacteraemia, pneumonia, pancreatic necrosis, or pancreatic insufficiency) within 6 months of randomisation. Analysis was by intention to treat. This trial is registered with the ISRCTN registry, ISRCTN97372133.Findings Between Feb 28, 2013, and March 1, 2017, 232 patients were randomly assigned to urgent ERCP with sphincterotomy (n=118) or conservative treatment (n=114). One patient from each group was excluded from the final analysis because of cholangitis (urgent ERCP group) and chronic pancreatitis (conservative treatment group) at admission. The primary endpoint occurred in 45 (38%) of 117 patients in the urgent ERCP group and in 50 (44%) of 113 patients in the conservative treatment group (risk ratio [RR] 0.87, 95% CI 0.64-1.18; p=0.37). No relevant differences in the individual components of the primary endpoint were recorded between groups, apart from the occurrence of cholangitis (

Published
2020

9. Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era

Author

Berden, F.A.C., Kievit, W., Baak, L.C., Bakker, C.M., Beuers, U., Boucher, C.A.B., Brouwer, J.T., Burger, D.M., Erpecum, K.J.L. van, Hoek, B. van, Hoepelman, A.I.M., Honkoop, P., Kerbert-Dreteler, M.J., Knegt, R.J. de, Koek, G.H., Nieuwkerk, C.M.J. van, Soest, H. van, Tan, A.C.I.T.L., Vrolijk, J.M., Drenth, J.P.H., Erasmus MC other, Virology, Surgery, Gastroenterology & Hepatology, Interne Geneeskunde, RS: NUTRIM - R2 - Gut-liver homeostasis, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, and Gastroenterology and Hepatology

Subjects
Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], SDG 3 - Good Health and Well-being, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], hepatitis C, Direct-acting antivirals, sofosbuvir, guidance, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]
Abstract

Item does not contain fulltext BACKGROUND: A new era for the treatment of chronic hepatitis C is about to transpire. With the introduction of the first-generation protease inhibitors the efficacy of hepatitis C treatment improved significantly. Since then, the therapeutic agenda has moved further forward with the recent approval of sofosbuvir and the expected approval of agents such as simeprevir and daclatasvir. This paper, developed parallel to the approval of sofosbuvir, is to serve as a guidance for the therapeutic management of chronic hepatitis C. METHODS: We performed a formal search through PubMed, Web of Science and ClinicalTrials.gov to identify all clinical trials that have been conducted with EMA-approved new agents in hepatitis C; for this version (April 2014) we focused on sofosbuvir. For each disease category, the evidence was reviewed and recommendations are based on GRADE. RESULTS: We identified 11 clinical trials with sofosbuvir and for each disease category recommendations for treatment are made. Not all disease categories were studied extensively and therefore in some cases we were unable to provide recommendations. CONCLUSION: The recent approval of sofosbuvir will most likely change the therapeutic landscape of chronic hepatitis C. The use of sofosbuvir-containing regimens can shorten the duration of therapy, increase efficacy and result in less side effects, compared with standard of care. The efficacy relative to standard of care needs to be weighed against the increased costs of sofosbuvir. With future approval of the other direct-acting antivirals, the outcome of hepatitis C treatment will likely improve further and this guidance will be updated.

Published
2014

10. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease

Author

Coenen, Marieke J.H., primary, de Jong, Dirk J., additional, van Marrewijk, Corine J., additional, Derijks, Luc J.J., additional, Vermeulen, Sita H., additional, Wong, Dennis R., additional, Klungel, Olaf H., additional, Verbeek, Andre L.M., additional, Hooymans, Piet M., additional, Peters, Wilbert H.M., additional, te Morsche, Rene H.M., additional, Newman, William G., additional, Scheffer, Hans, additional, Guchelaar, Henk-Jan, additional, Franke, Barbara, additional, Masclee, A.A.M., additional, Pierik, M., additional, Mares, W., additional, Hameeteman, W., additional, Wahab, P.J., additional, Seinen, H., additional, Rijk, M.C.M., additional, Harkema, I.M., additional, de Bièvre, M., additional, Oostenbrug, L., additional, Bakker, C.M., additional, Aquarius, M., additional, van Deursen, C., additional, van Nunen, A.B., additional, Goedhard, J.G., additional, Hamacher, M., additional, Gisbertz, I.A.M., additional, Brenninkmeijer, B.J., additional, Tan, A.C.I.T.L., additional, Aparicio-Pagés, M.N., additional, Witteman, E.M., additional, van Tuyl, S.A.C., additional, Breumelhof, R., additional, Stronkhorst, A., additional, Gilissen, L.P.L., additional, Schoon, E.J., additional, Tjhie-Wensing, J.W.M., additional, Temmerman, A., additional, Nicolaï, J.J., additional, van Bergeijk, J.D., additional, Bac, D.J., additional, Witteman, B.J.M., additional, Mahmmod, N., additional, Uil, J.J., additional, Akol, H., additional, Ouwendijk, R.J.T., additional, van Munster, I.P., additional, Pennings, M., additional, De Schryver, A.M.P., additional, van Ditzhuijsen, T.J.M., additional, Scheffer, R.C.H., additional, Römkens, T.E.H., additional, Schipper, D.L., additional, Bus, P.J., additional, Straathof, J.W.A., additional, Verhulst, M.L., additional, Boekema, P.J., additional, Kamphuis, J.T., additional, van Wijk, H.J., additional, Salemans, J.M.J.L., additional, Vermeijden, J.R., additional, van der Werf, S.D.J., additional, Verburg, R.J., additional, Spoelstra, P., additional, de Vree, J.M.L., additional, van der Linde, K., additional, Jebbink, H.J.A., additional, Jansen, M., additional, Holwerda, H., additional, van Bentem, N., additional, Kolkman, J.J., additional, Russel, M.G.V.M., additional, van Olffen, G.H., additional, Kerbert-Dreteler, M.J., additional, Bargeman, M., additional, Götz, J.M., additional, Schröder, R., additional, Jansen, J.M., additional, Bos, L.P., additional, Engels, L.G.J.B., additional, Romberg-Camps, M.J.L., additional, Keulen, E.T.P., additional, van Esch, A.A.J., additional, Drenth, J.P.H., additional, van Kouwen, M.C.A., additional, Wanten, G.J.A., additional, Bisseling, T.J., additional, van Vugt, M.W.J., additional, van de Meeberg, P.C., additional, van den Hazel, S.J., additional, Stuifbergen, W.N.H.M., additional, Grubben, M.J.A.L., additional, de Wit, U., additional, Dodemont, G.A.H., additional, Eichhorn, R.F., additional, van den Brande, J.M.H., additional, Naber, A. H.J., additional, van Soest, E.J., additional, Kingma, P.J., additional, Talstra, N.C., additional, Bruin, K.F., additional, Wolfhagen, F.H.J., additional, Hommes, D.W., additional, van der Veek, P.P.J., additional, Hardwick, J.C.A., additional, Stuyt, R.J., additional, Fidder, H.H., additional, Oldenburg, B., additional, and Tan, T.G., additional

Published
2015
Full Text
View/download PDF

11. Effects of a structured medication review by geriatrician and clinical pharmacologist on appropriateness of pharmacotherapy of frail elderly inpatients

Author

Lieverse, R.J., Berger, P., Van Dullemen, H., Ploeg, R.J., Vranken, J.H., Van Der Vegt, M.H., Van Voorthuizen, T., Otten, M.H., Nagengast, F.M., Joosten, F., Tan, A.C.I.T.L., Haarbrink, P., Te Velde, L.F., Ponssen, H.H., Koopman-Van Gemert, A.W.M.M., Jansen, J.B.M.J., Van Der Voort, P.H.J., Van Roon, E.N., Egbers, P.H.M., Gerritsen, R.T., Kuiper, M.A., Schippers, E.F., Van Dissel, J.T., Bosscha, K., Vos, A., Visser, M.R., Gooszen, H.G., Groningen Institute for Organ Transplantation, FarmacoTherapie, -Epidemiologie en -Economie, and Center for Liver, Digestive and Metabolic Diseases

Subjects
cholangitis, endoscopic retrograde cholangiopancreatography, acute pancreatitis, amylase blood level, differential diagnosis, letter, cholecystectomy, human, postoperative period, laboratory diagnosis, percutaneous transhepatic cholangiography
Published
2002

17. Atrial natriuretic peptide

Author

Tan, A.C.I.T.L. and Tan, A.C.I.T.L.

Abstract

Promotores : T. Benraad en P. Kloppenborg, Contains fulltext : mmubn000001_08730127x.pdf (publisher's version ) (Open Access)

Published
1989

18. The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection

Author

Buster, E.H.C.J., Baak, B.C., Bakker, C.M., Beuers, U.H.W., Brouwer, J.T., Drenth, J.P.H., Erpecum, K.J. van, Hoek, B. van, Honkoop, P., Kerbert-Dreteler, M.J., Koek, G.H., Nieuwkerk, K.M.J. van, Soest, H. van, Spek, B.W. van der, Tan, A.C.I.T.L., Vrolijk, J.M., Janssen, H.L.A., Interne Geneeskunde, RS: NUTRIM - R2 - Gut-liver homeostasis, Gastroenterology & Hepatology, Hematology, Gastroenterology and hepatology, CCA - Innovative therapy, Amsterdam Gastroenterology Endocrinology Metabolism, and Gastroenterology and Hepatology

Subjects
Hepatitis B virus, SDG 3 - Good Health and Well-being, antiviral therapy, guidelines, pregnancy, Molecular gastro-enterology and hepatology Membrane transport and intracellular motility [IGMD 2]
Abstract

Item does not contain fulltext In 2008, the Netherlands Association of Gastroenterologists and Hepatologists (Nederlands Vereniging van Maag-Darm-Leverartsen) published the Dutch national guidelines for the treatment of chronic hepatitis B virus infection. New insights into the treatment of chronic hepatitis B with relevance for clinical practice have been adopted in these concise, revised guidelines. The most important changes include the choice of initial antiviral therapy, licensing of tenofovir for the treatment of chronic hepatitis B and the management of antiviral resistance.

19. ATRIAL NATRIURETIC PEPTIDE CONCENTRATIONS DURING PREGNANCY

Author

Grace, A.A., primary, D'Souza, V., additional, Menon, R.K., additional, O'Brien, S., additional, Dandona, P., additional, Steegers, E.A.P., additional, Hein, P.R., additional, Groeneveld, E.A.M., additional, Jongsma, H.W., additional, Tan, A.C.I.T.L., additional, and Benraad, ThJ., additional

Published
1987
Full Text
View/download PDF

20. ANP in AMI

Author

Tan, A.C.I.T.L., primary, van Loenhout, T.T., additional, Lanfers, E.J.P., additional, Kloppenborg, P.W.C., additional, and Benraad, Th.J., additional

Published
1989
Full Text
View/download PDF

25. Early Omega-3-fatty acid infusion for reduction of organ failure and mortality in predicted severe acute pancreatitis: protocol for a multicenter randomized controlled trial (PLANCTON) by the Dutch Pancreatitis Study Group.

Author

Nagelhout, A., Stommel, M.W.J., Wolbrink, D.R.J., van den Berg, F.F., Dijkgraaf, M.G.W., van Santvoort, H.C., van der Poll, M.C.G., Issa, E., Dennison, A., Verdonk, R., van Hooft, J.E., Bruno, M.J., Bhalla, A., Tan, A.C.I.T.L., Inderson, A., Lammers, W.J., Voermans, R.P., Poley, J.W., Venneman, N.G., and Koehestanie, P.

Published
2024
Full Text
View/download PDF

27. Colonization of the gastrointestinal microbiota with Enterococcus and Staphylococcus predicts infected necrosis in patients with acute pancreatitis (POEMA): a prospective multicenter study.

Author

Pauw, H.S., van den Berg, F.F., Timmerhuis, H.C., Besselink, M.G.H., Issa, Y., Bruno, M.J., van Goor, H., Quispel, R., van de Vrie, W., Tan, A.C.I.T.L., Hadithi, M., Venneman, N.G., Witteman, B.J.M., Schwartz, M.P., van Wanrooij, R.L.J., Poen, A.C., van Duijvendijk, P., van Anten, M.P., Römkens, T., and Sieswerda, E.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results